Increased inflammation and lethality of Dusp1-/- mice in polymicrobial peritonitis models

Immunology

Volumn 131, Issue 3, 2010, Pages 395-404

  Hammer, Michael ^a   Echtenachter, Bernd ^b   Weighardt, Heike ^c   Jozefowski, Katrin ^d   Rose John, Stefan ^e   Männel, Daniela N ^b   Holzmann, Bernhard ^a   Lang, Roland ^a,d  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^e UNIVERSITY OF KIEL   (Germany)

Author keywords

Cytokines; Sepsis; Signalling

Indexed keywords

INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GROWTH; BACTERIAL PERITONITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; ESCHERICHIA COLI; INFLAMMATION; LETHALITY; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEPSIS;

ANIMALS; BACTERIAL LOAD; CECUM; COLON, ASCENDING; CYTOKINES; DISEASE MODELS, ANIMAL; DUAL SPECIFICITY PHOSPHATASE 1; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INFLAMMATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PERITONITIS; SEPSIS; STENTS;

EID: 78649418643     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2010.03313.x     Document Type: Article

References (46)

1. Buras JA, Holzmann B, Sitkovsky M. Animal models of sepsis: setting the stage. Nat Rev Drug Discov 2005; 4:854-65.
2. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4:499-511.
3. Lang R, Hammer M, Mages J. DUSP meet immunology: dual specificity MAPK phosphatases in control of the inflammatory response. J Immunol 2006; 177:7497-504.
4. Chi H, Barry SP, Roth RJ, Wu JJ, Jones EA, Bennett AM, Flavell RA. Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses. Proc Natl Acad Sci USA 2006; 103:2274-9.
5. Hammer M, Mages J, Dietrich H, Servatius A, Howells N, Cato AC, Lang R. Dual specificity phosphatase 1 (DUSP1) regulates a subset of LPS-induced genes and protects mice from lethal endotoxin shock. J Exp Med 2006; 203:15-20.
6. Salojin KV, Owusu IB, Millerchip KA, Potter M, Platt KA, Oravecz T. Essential role of MAPK phosphatase-1 in the negative control of innate immune responses. J Immunol 2006; 176:1899-907.
7. Zhao Q, Wang X, Nelin LD et al. MAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock. J Exp Med 2006; 203:131-40.
8. Wang X, Meng X, Kuhlman JR, Nelin LD, Nicol KK, English BK, Liu Y. Knockout of Mkp-1 enhances the host inflammatory responses to gram-positive bacteria. J Immunol 2007; 178:5312-20.
9. Frazier WJ, Wang X, Wancket LM, Li XA, Meng X, Nelin LD, Cato AC, Liu Y. Increased inflammation, impaired bacterial clearance, and metabolic disruption after gram-negative sepsis in Mkp-1-deficient mice. J Immunol 2009; 183:7411-19.
10. Echtenacher B, Falk W, Mannel DN, Krammer PH. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 1990; 145:3762-6.
11. Echtenacher B, Mannel DN, Hultner L. Critical protective role of mast cells in a model of acute septic peritonitis. Nature 1996; 381:75-7.
12. Echtenacher B, Weigl K, Lehn N, Mannel DN. Tumor necrosis factor-dependent adhesions as a major protective mechanism early in septic peritonitis in mice. Infect Immun 2001; 69:3550-5.
13. Zantl N, Uebe A, Neumann B, Wagner H, Siewert JR, Holzmann B, Heidecke CD, Pfeffer K. Essential role of gamma interferon in survival of colon ascendens stent peritonitis, a novel murine model of abdominal sepsis. Infect Immun 1998; 66:2300-9.
14. Maier S, Traeger T, Entleutner M et al. Cecal ligation and puncture versus colon ascendens stent peritonitis: two distinct animal models for polymicrobial sepsis. Shock 2004; 21:505-11.
15. Echtenacher B, Freudenberg MA, Jack RS, Mannel DN. Differences in innate defense mechanisms in endotoxemia and polymicrobial septic peritonitis. Infect Immun 2001; 69:7271-6.
16. Entleutner M, Traeger T, Westerholt A, Holzmann B, Stier A, Pfeffer K, Maier S, Heidecke CD. Impact of interleukin-12, oxidative burst, and iNOS on the survival of murine fecal peritonitis. Int J Colorectal Dis 2006; 21:64-70.
17. Emmanuilidis K, Weighardt H, Maier S et al. Critical role of Kupffer cell-derived IL-10 for host defense in septic peritonitis. J Immunol 2001; 167:3919-27.
18. Van Der Poll T, Marchant A, Buurman WA et al. Endogenous IL-10 protects mice from death during septic peritonitis. J Immunol 1995; 155:5397-401.
19. Dorfman K, Carrasco D, Gruda M, Ryan C, Lira SA, Bravo R. Disruption of the erp/mkp-1 gene does not affect mouse development: normal MAP kinase activity in ERP/MKP-1-deficient fibroblasts. Oncogene 1996; 13:925-31.
20. Echtenacher B, Hultner L, Mannel DN. Cellular and molecular mechanisms of TNF protection in septic peritonitis. J Inflamm 1995; 47:85-9.
21. Hammer M, Mages J, Dietrich H, Schmitz F, Striebel F, Murray PJ, Wagner H, Lang R. Control of dual-specificity phosphatase-1 expression in activated macrophages by IL-10. Eur J Immunol 2005; 35:2991-3001.
22. Wiese M, Castiglione K, Hensel M, Schleicher U, Bogdan C, Jantsch J. Small interfering RNA (siRNA) delivery into murine bone marrow-derived macrophages by electroporation. J Immunol Methods 2010; 353:102-10.
23. Weighardt H, Kaiser-Moore S, Vabulas RM, Kirschning CJ, Wagner H, Holzmann B. Cutting edge: myeloid differentiation factor 88 deficiency improves resistance against sepsis caused by polymicrobial infection. J Immunol 2002; 169:2823-7.
24. Feterowski C, Novotny A, Kaiser-Moore S, Muhlradt PF, Rossmann-Bloeck T, Rump M, Holzmann B, Weighardt H. Attenuated pathogenesis of polymicrobial peritonitis in mice after TLR2 agonist pre-treatment involves ST2 up-regulation. Int Immunol 2005; 17:1035-46.
25. Weighardt H, Mages J, Jusek G, Kaiser-Moore S, Lang R, Holzmann B. Organ-specific role of MyD88 for gene regulation during polymicrobial peritonitis. Infect Immun 2006; 74:3618-32.
26. Dalrymple SA, Lucian LA, Slattery R, McNeil T, Aud DM, Fuchino S, Lee F, Murray R. Interleukin-6-deficient mice are highly susceptible to Listeria monocytogenes infection: correlation with inefficient neutrophilia. Infect Immun 1995; 63:2262-8.
27. Sutherland RE, Olsen JS, McKinstry A, Villalta SA, Wolters PJ. Mast cell IL-6 improves survival from Klebsiella pneumonia and sepsis by enhancing neutrophil killing. J Immunol 2008; 181:5598-605.
28. Riedemann NC, Neff TA, Guo RF, Bernacki KD, Laudes IJ, Sarma JV, Lambris JD, Ward PA. Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression. J Immunol 2003; 170:503-7.
29. Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 2006; 80:227-36.
30. Peck-Palmer OM, Unsinger J, Chang KC, Davis CG, McDunn JE, Hotchkiss RS. Deletion of MyD88 markedly attenuates sepsis-induced T and B lymphocyte apoptosis but worsens survival. J Leukoc Biol 2008; 83:1009-18.
31. Andonegui G, Zhou H, Bullard D et al. Mice that exclusively express TLR4 on endothelial cells can efficiently clear a lethal systemic Gram-negative bacterial infection. J Clin Invest 2009; 119:1921-30.
32. Remick DG, Bolgos G, Copeland S, Siddiqui J. Role of interleukin-6 in mortality from and physiologic response to sepsis. Infect Immun 2005; 73:2751-7.
33. Remick DG, Bolgos GR, Siddiqui J, Shin J, Nemzek JA. Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 2002; 17:463-7.
34. Frink M, Van Griensven M, Kobbe P, Brin T, Zeckey C, Vaske B, Krettek C, Hildebrand F. IL-6 predicts organ dysfunction and mortality in patients with multiple injuries. Scand J Trauma Resusc Emerg Med 2009; 17:49.
35. Pajkrt D, Camoglio L, Tiel-van Buul MC et al. Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: effect of timing of recombinant human IL-10 administration. J Immunol 1997; 158:3971-7.
36. Dalrymple SA, Slattery R, Aud DM, Krishna M, Lucian LA, Murray R. Interleukin-6 is required for a protective immune response to systemic Escherichia coli infection. Infect Immun 1996; 64:3231-5.
37. Van Enckevort FH, Sweep CG, Span PN, Netea MG, Hermus AR, Kullberg BJ. Reduced adrenal response and increased mortality after systemic Klebsiella pneumoniae infection in interleukin-6-deficient mice. Eur Cytokine Netw 2001; 12:581-6.
38. Mitsuyama K, Sata M, Rose-John S. Interleukin-6 trans-signaling in inflammatory bowel disease. Cytokine Growth Factor Rev 2006; 17:451-61.
39. Nowell MA, Richards PJ, Horiuchi S, Yamamoto N, Rose-John S, Topley N, Williams AS, Jones SA. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J Immunol 2003; 171:3202-9.
40. Mees ST, Toellner S, Marx K, Faendrich F, Kallen KJ, Schroeder J, Haier J, Kahlke V. Inhibition of interleukin-6-transsignaling via gp130-Fc in hemorrhagic shock and sepsis. J Surg Res 2009; 157:235-42.
41. Vyas D, Javadi P, Dipasco PJ, Buchman TG, Hotchkiss RS, Coopersmith CM. Early antibiotic administration but not antibody therapy directed against IL-6 improves survival in septic mice predicted to die on basis of high IL-6 levels. Am J Physiol Regul Integr Comp Physiol 2005; 289:R1048-R1053.
42. Schaljo B, Kratochvill F, Gratz N et al. Tristetraprolin is required for full anti-inflammatory response of murine macrophages to IL-10. J Immunol 2009; 183:1197-206.
43. Klintman D, Li X, Santen S, Schramm R, Jeppsson B, Thorlacius H. p38 mitogen-activated protein kinase-dependent chemokine production, leukocyte recruitment, and hepatocellular apoptosis in endotoxemic liver injury. Ann Surg 2005; 242:830-8, discussion 838-9.
44. Asaduzzaman M, Wang Y, Thorlacius H. Critical role of p38 mitogen-activated protein kinase signaling in septic lung injury. Crit Care Med 2008; 36:482-8.
45. Van Den Blink B, Juffermans NP, Ten Hove T, Schultz MJ, Van Deventer SJ, Van Der Poll T, Peppelenbosch MP. p38 mitogen-activated protein kinase inhibition increases cytokine release by macrophages in vitro and during infection in vivo. J Immunol 2001; 166:582-7.
46. Jeffrey KL, Camps M, Rommel C, Mackay CR. Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses. Nat Rev Drug Discov 2007; 6:391-403.